Surgery for metastatic renal cell cancer

Shomik Sengupta, Bradley C. Leibovich, Michael L. Blute, Horst Zincke

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) often presents in its metastatic form, or progresses after curative treatment. While the management of metastatic RCC has historically been mainly surgical, contemporary approaches often incorporate systemic immunotherapy. This review examines the current indications and scope of surgical treatment of patients with metastatic RCC. Surgery is sometimes indicated for symptom palliation at either the primary or secondary sites. However, other less invasive therapies may be equally effective, and should be considered carefully. Cytoreductive surgery prior to immunotherapy appears to confer a survival advantage, but only selected patients are suitable for this treatment regimen. Primary immunotherapy followed by surgical removal of the tumour in partial responders is an alternative treatment strategy, which has not yet been evaluated as in randomized trials. As immunotherapy develops further, the precise timing and role of surgery in multimodality treatment will need to be carefully evaluated. Occasionally, the complete surgical excision of metastases, and the primary tumour, if present, is feasible and this may prolong survival. Empirically, it would seem that such patients should also be treated with adjuvant immunotherapy, as eventual relapse is frequent. Surgery with the aim of inducing spontaneous tumour regression is not justifiable, given the rarity of this phenomenon.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalWorld Journal of Urology
Volume23
Issue number3
DOIs
StatePublished - Jul 2005

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Therapeutics
Neoplasms
Survival
Neoplasm Metastasis
Recurrence

Keywords

  • Carcinoma
  • Metastasis
  • Neoplasm
  • Nephrectomy
  • Renal cell
  • Surgery

ASJC Scopus subject areas

  • Urology

Cite this

Sengupta, S., Leibovich, B. C., Blute, M. L., & Zincke, H. (2005). Surgery for metastatic renal cell cancer. World Journal of Urology, 23(3), 155-160. https://doi.org/10.1007/s00345-005-0504-6

Surgery for metastatic renal cell cancer. / Sengupta, Shomik; Leibovich, Bradley C.; Blute, Michael L.; Zincke, Horst.

In: World Journal of Urology, Vol. 23, No. 3, 07.2005, p. 155-160.

Research output: Contribution to journalReview article

Sengupta, S, Leibovich, BC, Blute, ML & Zincke, H 2005, 'Surgery for metastatic renal cell cancer', World Journal of Urology, vol. 23, no. 3, pp. 155-160. https://doi.org/10.1007/s00345-005-0504-6
Sengupta S, Leibovich BC, Blute ML, Zincke H. Surgery for metastatic renal cell cancer. World Journal of Urology. 2005 Jul;23(3):155-160. https://doi.org/10.1007/s00345-005-0504-6
Sengupta, Shomik ; Leibovich, Bradley C. ; Blute, Michael L. ; Zincke, Horst. / Surgery for metastatic renal cell cancer. In: World Journal of Urology. 2005 ; Vol. 23, No. 3. pp. 155-160.
@article{521f70e617494db7b6f158033400300d,
title = "Surgery for metastatic renal cell cancer",
abstract = "Renal cell carcinoma (RCC) often presents in its metastatic form, or progresses after curative treatment. While the management of metastatic RCC has historically been mainly surgical, contemporary approaches often incorporate systemic immunotherapy. This review examines the current indications and scope of surgical treatment of patients with metastatic RCC. Surgery is sometimes indicated for symptom palliation at either the primary or secondary sites. However, other less invasive therapies may be equally effective, and should be considered carefully. Cytoreductive surgery prior to immunotherapy appears to confer a survival advantage, but only selected patients are suitable for this treatment regimen. Primary immunotherapy followed by surgical removal of the tumour in partial responders is an alternative treatment strategy, which has not yet been evaluated as in randomized trials. As immunotherapy develops further, the precise timing and role of surgery in multimodality treatment will need to be carefully evaluated. Occasionally, the complete surgical excision of metastases, and the primary tumour, if present, is feasible and this may prolong survival. Empirically, it would seem that such patients should also be treated with adjuvant immunotherapy, as eventual relapse is frequent. Surgery with the aim of inducing spontaneous tumour regression is not justifiable, given the rarity of this phenomenon.",
keywords = "Carcinoma, Metastasis, Neoplasm, Nephrectomy, Renal cell, Surgery",
author = "Shomik Sengupta and Leibovich, {Bradley C.} and Blute, {Michael L.} and Horst Zincke",
year = "2005",
month = "7",
doi = "10.1007/s00345-005-0504-6",
language = "English (US)",
volume = "23",
pages = "155--160",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Surgery for metastatic renal cell cancer

AU - Sengupta, Shomik

AU - Leibovich, Bradley C.

AU - Blute, Michael L.

AU - Zincke, Horst

PY - 2005/7

Y1 - 2005/7

N2 - Renal cell carcinoma (RCC) often presents in its metastatic form, or progresses after curative treatment. While the management of metastatic RCC has historically been mainly surgical, contemporary approaches often incorporate systemic immunotherapy. This review examines the current indications and scope of surgical treatment of patients with metastatic RCC. Surgery is sometimes indicated for symptom palliation at either the primary or secondary sites. However, other less invasive therapies may be equally effective, and should be considered carefully. Cytoreductive surgery prior to immunotherapy appears to confer a survival advantage, but only selected patients are suitable for this treatment regimen. Primary immunotherapy followed by surgical removal of the tumour in partial responders is an alternative treatment strategy, which has not yet been evaluated as in randomized trials. As immunotherapy develops further, the precise timing and role of surgery in multimodality treatment will need to be carefully evaluated. Occasionally, the complete surgical excision of metastases, and the primary tumour, if present, is feasible and this may prolong survival. Empirically, it would seem that such patients should also be treated with adjuvant immunotherapy, as eventual relapse is frequent. Surgery with the aim of inducing spontaneous tumour regression is not justifiable, given the rarity of this phenomenon.

AB - Renal cell carcinoma (RCC) often presents in its metastatic form, or progresses after curative treatment. While the management of metastatic RCC has historically been mainly surgical, contemporary approaches often incorporate systemic immunotherapy. This review examines the current indications and scope of surgical treatment of patients with metastatic RCC. Surgery is sometimes indicated for symptom palliation at either the primary or secondary sites. However, other less invasive therapies may be equally effective, and should be considered carefully. Cytoreductive surgery prior to immunotherapy appears to confer a survival advantage, but only selected patients are suitable for this treatment regimen. Primary immunotherapy followed by surgical removal of the tumour in partial responders is an alternative treatment strategy, which has not yet been evaluated as in randomized trials. As immunotherapy develops further, the precise timing and role of surgery in multimodality treatment will need to be carefully evaluated. Occasionally, the complete surgical excision of metastases, and the primary tumour, if present, is feasible and this may prolong survival. Empirically, it would seem that such patients should also be treated with adjuvant immunotherapy, as eventual relapse is frequent. Surgery with the aim of inducing spontaneous tumour regression is not justifiable, given the rarity of this phenomenon.

KW - Carcinoma

KW - Metastasis

KW - Neoplasm

KW - Nephrectomy

KW - Renal cell

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=23744435591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744435591&partnerID=8YFLogxK

U2 - 10.1007/s00345-005-0504-6

DO - 10.1007/s00345-005-0504-6

M3 - Review article

VL - 23

SP - 155

EP - 160

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -